Drug General Information (ID: DDI5JGVNB3)
  Drug Name Droxidopa Drug Info Methylene blue Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Vasopressors Antidotes/Mao Inhibitors
  Structure

 Mechanism of Droxidopa-Methylene blue Interaction (Severity Level: Moderate)
     Additive hypertensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Droxidopa Methylene blue
      Mechanism Hypertensive effects Hypertensive effects
      Key Mechanism Factor 1
Factor Name Hypertensive effects
Factor Description Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
      Mechanism Description
  • Additive hypertensive effects by the combination of Droxidopa and Methylene blue 

Recommended Action
      Management Concomitant use of droxidopa with nonselective MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine) should be avoided. Selective MAO-B inhibitors such as rasagiline and selegiline were permitted in droxidopa clinical trials.

References
1 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.